Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
16 - Pharmacogenomics Associated with Therapy for Acid-Related Disorders
from II - Therapeutic Areas
Published online by Cambridge University Press: 05 June 2012
Book contents
- Frontmatter
- Contents
- Contributors
- Introduction
- I Critical Concepts
- II Therapeutic Areas
- 10 Oncologic Drugs
- 11 Pharmacogenetics and Pharmacogenomics of Cardiovascular Disease
- 12 Statin-Induced Muscle Toxicity
- 13 Genomics of the Drug-Induced Long-QT Syndrome
- 14 Pharmacogenetics of Diabetes
- 15 Pharmacogenetics – Therapeutic Area – Respiratory
- 16 Pharmacogenomics Associated with Therapy for Acid-Related Disorders
- 17 Pharmacogenetics of Rheumatology: Focus on Rheumatoid Arthritis
- 18 Pharmacogenetics of Obstetric Therapeutics
- 19 Pharmacogenomics of Psychiatric Drugs
- 20 Pain and Anesthesia
- 21 HIV and Antiretroviral Therapy
- 22 Application of Pharmacogenetics and Pharmacogenomics in Pediatrics: What Makes Children Different?
- References
Summary
Peptic ulcer and gastroesophageal reflux disease (GERD) are common benign upper gastrointestinal disorders. The major causes of peptic ulcer are Helicobacter pylori (H. pylori) infection and nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin. No matter whether caused by H. pylori, NSAIDs, or both, however, gastric acid plays a markedly important role in the pathogenesis of peptic ulcer. Furthermore, the major cause of GERD is the reflux of gastric acid from the stomach to the esophagus. Gastric acid therefore acts as the most important pathogenic factor of upper gastrointestinal disorders, and acid inhibition with a proton pump inhibitor (PPI) is the major strategy against them. PPIs in combination with one or two antibiotics are also used for the eradication of H. pylori.
PPIs are substitutes of benzimidazole and are mainly metabolized by the cytochrome P450 (CYP) system in the liver (1). The principal enzyme in this metabolism is CYP2C19 (1), although CYP3A4 also plays a role (2–6). Given the presence of interindividual differences in CYP2C19 activity, the pharmacokinetics (PKs) and pharmacodynamics (PDs) of PPIs largely depend on polymorphisms in CYP2C19 (7).
- Type
- Chapter
- Information
- Principles of Pharmacogenetics and Pharmacogenomics , pp. 175 - 187Publisher: Cambridge University PressPrint publication year: 2012
References
Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazoleClin Pharmacokinet 1996 31 9Google Scholar
Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylatorsTher Drug Monit 1990 12 415Google Scholar
Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjectsPharmacogenetics 1992 2 25Google Scholar
Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4ʹ-hydroxylation recruited from an Oriental populationJ Pharmacol Exp Ther 1992 262 1195Google Scholar
Identification of the human P450 enzymes involved in lansoprazole metabolismJ Pharmacol Exp Ther 1996 277 805Google Scholar
Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samplesJ Pharmacol Exp Ther 1997 283 434Google Scholar
CYP2C19 genotype status and effect of omeprazole on intragastric pH in humansClin Pharmacol Ther 1999 65 552Google Scholar
Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2Clin Pharmacol Ther 2002 72 62Google Scholar
Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and OrientalsTher Drug Monit 1994 16 214Google Scholar
Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant alleleJ Pharmacol Exp Ther 1997 281 604Google Scholar
Genetic polymorphism of (S)-mephenytoin 4ʹ-hydroxylation in populations of African descentBr J Clin Pharmacol 1999 48 402Google Scholar
Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotypeClin Pharmacol Ther 1996 60 138Google Scholar
Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of ZimbabweClin Pharmacol Ther 1995 57 656Google Scholar
Genetic analysis of the S-mephenytoin polymorphism in a Chinese populationClin Pharmacol Ther 1995 58 404Google Scholar
Genotyping of S-mephenytoin 4ʹ-hydroxylation in an extended Japanese populationClin Pharmacol Ther 1996 60 661Google Scholar
CYP2C19 genotype and phenotype determined by omeprazole in a Korean populationPharmacogenetics 1996 6 547Google Scholar
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4ʹ-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the worldPharmacogenetics 1999 9 539Google Scholar
Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in JapaneseMol Pharmacol 1994 46 594Google Scholar
The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humansJ Biol Chem 1994 269 15419Google Scholar
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClin Pharmacol Ther 2006 79 103Google Scholar
Effect of CYP2C19*17 gene variant on eradication in peptic ulcer patientsEur J Clin Pharmacol 2006 62 877Google Scholar
CYP2C19 pharmacogenomics associated with therapy of infection and gastro-esophageal reflux diseases with a proton pump inhibitorPharmacogenomics 2007 8 1199Google Scholar
Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizersAliment Pharmacol Ther 2002 16 1811Google Scholar
Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pHAliment Pharmacol Ther 2001 15 1929Google Scholar
Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groupsAliment Pharmacol Ther 2002 16 837Google Scholar
Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype statusClin Pharmacol Ther 2004 76 290Google Scholar
Influence of cytochrome P450 2c19 polymorphism on intragastric acidity during treatment with high-dose esomeprazole and pantoprazoleGastroenterology 2007 132Google Scholar
Symptomatic gastroesophageal reflux: incidence and precipitating factorsAm J Dig Dis 1976 21 953Google Scholar
Lansoprazole versus ranitidine for the treatment of reflux oesophagitis. UK Lansoprazole Clinical Research GroupAliment Pharmacol Ther 1995 9 145Google Scholar
The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux diseaseAliment Pharmacol Ther 1995 9 15Google Scholar
Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazoleClin Pharmacol Ther 2002 72 453Google Scholar
The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphismAliment Pharmacol Ther 2003 17 965Google Scholar
Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitisJ Gastroenterol Hepatol 2007 22 222Google Scholar
Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitorsAm J Gastroenterol 1998 93 763Google Scholar
Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitisJ Gastroenterol Hepatol 2001 16 1191Google Scholar
Combined gastric and oesophageal 24-hour pH monitoring and oesophageal manometry in patients with reflux disease, resistant to treatment with omeprazoleAliment Pharmacol Ther 1990 4 485Google Scholar
Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposureAm J Gastroenterol 2003 98 545Google Scholar
Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19Clin Pharmacol Ther 2001 70 484Google Scholar
Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitorsAliment Pharmacol Ther 2001 15 1351Google Scholar
Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjectsGastroenterology 1998 115 1335Google Scholar
Therapeutic approaches to reflux disease, focusing on acid secretionJ Gastroenterol 2003 38 13Google Scholar
Endoscopic analysis of gastric ulcer after one week's treatment with omeprazole and rabeprazole in relation to CYP2C19 genotypeDig Dis Sci 2008 53 933Google Scholar
Hypotheses on the pathogenesis and natural history of -induced inflammationGastroenterology 1992 102 720Google Scholar
Symptoms and risk factors of infection in a cohort of epidemiologistsGastroenterology 1992 102 41Google Scholar
Current concepts in the management of infection: the Maastricht III Consensus ReportGut 2007 56 772Google Scholar
Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agentsEur J Clin Microbiol Infect Dis 1989 8 888Google Scholar
Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juiceGastroenterology 1996 111 358Google Scholar
Oxygen concentration influences proton pump inhibitor activity against in vitroAntimicrob Agents Chemother 1996 40 1531Google Scholar
Effect of genetic differences in omeprazole metabolism on cure rates for infection and peptic ulcerAnn Intern Med 1998 129 1027Google Scholar
A multicenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of in Japanese peptic ulcer patientsHelicobacter 2001 6 254Google Scholar
Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolismBr J Clin Pharmacol 1994 37 597Google Scholar
Oxidative metabolism of clarithromycin in the presence of human liver microsomes. Major role for the cytochrome P4503A (CYP3A) subfamilyDrug Metab Dispos 1997 25 623Google Scholar
Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humansClin Pharmacol Ther 1999 66 265Google Scholar
Effect of genotypic differences in CYP2C19 on cure rates for infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycinClin Pharmacol Ther 2001 69 158Google Scholar
Effects of CYP2C19 gene polymorphism on cure rates for infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxicillin and clarithromycin in JapanDig Liver Dis 2001 33 671Google Scholar
Randomized open trial for comparison of proton pump inhibitors in triple therapy for infection in relation to CYP2C19 genotypeJ Gastroenterol Hepatol 2002 17 748Google Scholar
Point mutations in the 23S rRNA gene of associated with different levels of clarithromycin resistanceJ Antimicrob Chemother 1997 40 283Google Scholar
A PCR-oligonucleotide ligation assay to determine the prevalence of 23S rRNA gene mutations in clarithromycin-resistant Antimicrob Agents Chemother 1997 41 712Google Scholar
PCR-restriction fragment length polymorphism can also detect point mutation A2142C in the 23S rRNA gene, associated with resistance to clarithromycinAntimicrob Agents Chemother 2002 46 1156Google Scholar
Influence of CYP2C19 polymorphism and genotype determined from gastric tissue samples on response to triple therapy for infectionClin Gastroenterol Hepatol 2005 3 564Google Scholar
Primary and acquired resistance to clarithromycin, metronidazole, and amoxicillin – influence on treatment outcomeAm J Gastroenterol 1998 93 386Google Scholar
Double-blind trial of omeprazole and amoxicillin to cure infection in patients with duodenal ulcersGastroenterology 1995 108 1412Google Scholar
High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillinHepatogastroenterology 2003 50 2274Google Scholar
Effects of genotypic differences in CYP2C19 status on cure rates for infection by dual therapy with rabeprazole plus amoxicillinPharmacogenetics 2001 11 341Google Scholar
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of resistant to both metronidazole and clarithromycinHelicobacter 2003 8 310Google Scholar
Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of Clin Pharmacol Ther 2007 81 521Google Scholar
Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphismsGastroenterology 2007 133 465Google Scholar
Upper gastrointestinal ulcer in Japanese patients taking low dose aspirinGastroenterology 2008 134 A736Google Scholar
Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acidBr J Clin Pharmacol 2005 60 623Google Scholar
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Clin Pharmacol Ther 1999 66 528Google Scholar
The clinical role of cytochrome p450 genotypes in managementAm J Gastroenterol 2003 98 1010Google Scholar
Concomitant dosing of famotidine with a triple therapy increases the cure rates of infections in patients with the homozygous extensive metabolizer genotype of CYP2C19Aliment Pharmacol Ther 2005 21 491Google Scholar
Efficacy of low-dose proton pump inhibitor (PPI) in the eradication of following combination PPI/AC therapy in JapanHepatogastroenterology 2007 54 649Google Scholar
H+/K+-adenosine triphosphatase mRNA in gastric fundic gland mucosa in patients infected with Scand J Gastroenterol 1999 34 384Google Scholar
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for infection after the standard triple therapyEur J Clin Pharmacol 2007 63 743Google Scholar